Loading stock data…
BridgeBio Pharma, Inc. (BBIO)
$72.01+1.77 (+2.52%)
After Hours$72.51+0.50 (+0.69%)· Last close Jun 29
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BridgeBio Pharma, Inc. in the Healthcare sector is trading at $72.01 with a market capitalization of $12.8B. Wall Street consensus targets $102.28 (23 analysts), implying a +42.0% move over the next 12 months. The stock is currently 15% below its 52-week high of $84.94, remaining 5.8% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +42.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $194.51M↑ | $154.18M↑ | $120.70M↑ | $110.56M↓ | $116.63M |
| Gross Profit | $184.58M↑ | $146.07M↑ | $114.14M↑ | $106.91M↓ | $113.99M |
| Operating Income | -$105.96M↑ | -$128.43M↑ | -$136.36M↓ | -$133.47M↓ | -$103.80M |
| Net Income | -$164.04M↑ | -$192.86M↓ | -$182.74M↓ | -$181.90M↓ | -$167.42M |
Peer Comparison
JNJUNHPFE
Fundamentals
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.02
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
31.67%
Volume
Today's trading volume
3.25M
Recent News
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Brands, and More
Mid-Day Stocks: Stocks are trading lower on Wednesday, as oil and yields move higher. Once again, it was “Welcome back, my friends to the show that never ends.” On cue, the never-say-die stock market shook off early worries and all the major indices closed higher on Tuesday. Like the proverbial broken record, the S&P 500 ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Bra
Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls
Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls
Does FDA Priority Review for First LGMD Therapy Change The Bull Case For BridgeBio Pharma (BBIO)?
BridgeBio Pharma recently announced that the FDA has accepted and granted Priority Review to its New Drug Application for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9, with a PDUFA target action date set for November 27, 2026. If approved, BBP-418 would be the first and only therapy for LGMD2I/R9 and the first approved treatment for any form of limb-girdle muscular dystrophy, highlighting its potential importance for a rare disease community with limited options. We will...
Allogene CEO to step down; Agios drug fails key test
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
Intel downgraded, Marvell upgraded: Wall Street's top analyst calls
Intel downgraded, Marvell upgraded: Wall Street's top analyst calls